Retroviral vectors: new applications for an old tool

Barquinero, Jordi; Eixarch, Herena; Pérez-Melgosa, M

doi:10.1038/sj.gt.3302363

Cited by 105 publications

(67 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Retroviral vectors are enveloped RNA viral vectors 80–130 nm in diameter, with a genome of 8–11 kb [50]. Retroviral vectors can deliver transgenes into the cell via an interaction between their envelope and cell surface receptors [50].…”

Section: Nano-sized Carriers For Gene Therapy Of Peritoneal Fibrosis mentioning

confidence: 99%

Section: Nano-sized Carriers For Gene Therapy Of Peritoneal Fibrosis mentioning

confidence: 99%

“…Retroviral vectors can deliver transgenes into the cell via an interaction between their envelope and cell surface receptors [50]. Unlike adenoviral vectors, retroviral vectors only deliver transgenes into dividing cells [50]. They can incorporate transgenes into the host genome and are therefore capable of long-term transgene expression [38,50].…”

Section: Nano-sized Carriers For Gene Therapy Of Peritoneal Fibrosis mentioning

confidence: 99%

“…Unlike adenoviral vectors, retroviral vectors only deliver transgenes into dividing cells [50]. They can incorporate transgenes into the host genome and are therefore capable of long-term transgene expression [38,50]. Cultured human peritoneal mesothelial cells transfected with small interfering RNA (siRNA) targeted to connective tissue growth factor (CTGF) using retroviral vectors knocked down CTGF expression and inhibited extracellular matrix production, including fibronectin, collagen I, and laminin, as well as vascular endothelial growth factor expression under stimulation by TGF-β 1 [38].…”

Section: Nano-sized Carriers For Gene Therapy Of Peritoneal Fibrosis mentioning

confidence: 99%

See 3 more Smart Citations

Nano-sized carriers in gene therapy for peritoneal fibrosisin vivo

Igarashi

Hoshino

Ookawara

et al. 2017

Nano Reviews & Experiments

View full text Add to dashboard Cite

Peritoneal fibrosis is a crucial complication in patients receiving peritoneal dialysis. It is a major pathological feature of peritoneal membrane failure, which leads to withdrawal of peritoneal dialysis. No specific therapy has yet been established for the treatment of peritoneal fibrosis. However, gene therapy may be a viable option, and various nano-sized carriers, including viral and non-viral vectors, have been shown to enhance the delivery and efficacy of gene therapy for peritoneal fibrosis in vivo. This review focuses on the use of nano-sized carriers in gene therapy of peritoneal fibrosis in vivo.

show abstract

Section: Nano-sized Carriers For Gene Therapy Of Peritoneal Fibrosis mentioning

confidence: 99%

Section: Nano-sized Carriers For Gene Therapy Of Peritoneal Fibrosis mentioning

confidence: 99%

Section: Nano-sized Carriers For Gene Therapy Of Peritoneal Fibrosis mentioning

confidence: 99%

Section: Nano-sized Carriers For Gene Therapy Of Peritoneal Fibrosis mentioning

confidence: 99%

See 2 more Smart Citations

Nano-sized carriers in gene therapy for peritoneal fibrosisin vivo

Igarashi

Hoshino

Ookawara

et al. 2017

Nano Reviews & Experiments

View full text Add to dashboard Cite

show abstract

“…[3] The primary feature of RNA-based viral vectors, such as retroviruses, is that they are capable of long-term transgene expression through gene integration. [4,5] DNA-based viral vectors normally result in transgene expression in episomal form without integration. [6] Major features of the most commonly used viral vectors are summarized in table I.…”

Section: Virus-based Gene Delivery Systemsmentioning

confidence: 99%

Advances in Gene Delivery Systems

et al. 2011

View full text Add to dashboard Cite

The transfer of genes into cells, both in vitro and in vivo, is critical for studying gene function and conducting gene therapy. Methods that utilize viral and nonviral vectors, as well as physical approaches, have been explored. Viral vector-mediated gene transfer employs replication-deficient viruses such as retro-virus, adenovirus, adeno-associated virus and herpes simplex virus. A major advantage of viral vectors is their high gene delivery efficiency. The nonviral vectors developed so far include cationic liposomes, cationic polymers, synthetic peptides and naturally occurring compounds. These nonviral vectors appear to be highly effective in gene delivery to cultured cells in vitro but are significantly less effective in vivo. Physical methods utilize mechanical pressure, electric shock or hydrodynamic force to transiently permeate the cell membrane to transfer DNA into target cells. They are simpler than viral-and nonviral-based systems and highly effective for localized gene delivery. The past decade has seen significant efforts to establish the most desirable method for safe, effective and target-specific gene delivery, and good progress has been made. The objectives of this review are to (i) explain the rationale for the design of viral, nonviral and physical methods for gene delivery; (ii) provide a summary on recent advances in gene transfer technology; (iii) discuss advantages and disadvantages of each of the most commonly used gene delivery methods; and (iv) provide future perspectives.

show abstract

Gene Therapy for Cardiovascular Disease: Inserting New Genes, Regulating the Expression of Native Genes, and Correcting Genetic Defects

Jovin¹,

Giordano²

2007

Cardiovascular Genetics and Genomics for the Cardiologist

View full text Add to dashboard Cite

Retroviral vectors: new applications for an old tool

Cited by 105 publications

References 57 publications

Nano-sized carriers in gene therapy for peritoneal fibrosisin vivo

Nano-sized carriers in gene therapy for peritoneal fibrosisin vivo

Advances in Gene Delivery Systems

Gene Therapy for Cardiovascular Disease: Inserting New Genes, Regulating the Expression of Native Genes, and Correcting Genetic Defects

Contact Info

Product

Resources

About